Immuneering Corporation (NASDAQ:IMRX) Director Thomas J. Schall Acquires 9,500 Shares

Immuneering Corporation (NASDAQ:IMRX - Get Free Report) Director Thomas J. Schall purchased 9,500 shares of Immuneering stock in a transaction dated Friday, June 27th. The shares were purchased at an average price of $3.66 per share, for a total transaction of $34,770.00. Following the completion of the acquisition, the director owned 52,885 shares of the company's stock, valued at approximately $193,559.10. The trade was a 21.90% increase in their position. The acquisition was disclosed in a document filed with the SEC, which is accessible through this hyperlink.

Immuneering Stock Down 5.6%

IMRX traded down $0.20 during trading on Thursday, reaching $3.39. 908,546 shares of the stock traded hands, compared to its average volume of 2,548,284. The stock's 50-day moving average is $1.92 and its 200 day moving average is $1.81. Immuneering Corporation has a 12 month low of $1.00 and a 12 month high of $3.87. The stock has a market capitalization of $122.01 million, a PE ratio of -1.73 and a beta of 0.38.

Immuneering (NASDAQ:IMRX - Get Free Report) last announced its quarterly earnings data on Monday, May 5th. The company reported ($0.42) EPS for the quarter, missing the consensus estimate of ($0.41) by ($0.01). As a group, equities research analysts anticipate that Immuneering Corporation will post -1.86 EPS for the current year.

Institutional Investors Weigh In On Immuneering

Hedge funds and other institutional investors have recently made changes to their positions in the business. Tang Capital Management LLC bought a new stake in Immuneering in the 4th quarter worth about $27,000. Jane Street Group LLC bought a new position in Immuneering in the 1st quarter worth about $32,000. Marshall Wace LLP bought a new stake in shares of Immuneering during the fourth quarter valued at about $47,000. First Manhattan CO. LLC. purchased a new position in shares of Immuneering during the 4th quarter valued at $71,000. Finally, XTX Topco Ltd increased its holdings in shares of Immuneering by 177.2% in the fourth quarter. XTX Topco Ltd now owns 32,650 shares of the company's stock worth $72,000 after purchasing an additional 20,871 shares during the period. 67.65% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

A number of equities analysts have recently commented on IMRX shares. Mizuho lifted their price target on shares of Immuneering from $8.00 to $10.00 and gave the stock an "outperform" rating in a report on Wednesday, June 18th. Chardan Capital reaffirmed a "buy" rating and set a $13.00 target price on shares of Immuneering in a report on Wednesday, June 18th. Oppenheimer decreased their price target on Immuneering from $25.00 to $21.00 and set an "outperform" rating for the company in a research note on Wednesday, May 7th. Finally, Needham & Company LLC reaffirmed a "buy" rating and issued a $9.00 price objective on shares of Immuneering in a research note on Wednesday, June 18th. One equities research analyst has rated the stock with a sell rating and four have assigned a buy rating to the company's stock. According to data from MarketBeat, Immuneering has an average rating of "Moderate Buy" and an average price target of $13.25.

About Immuneering

Immuneering Corporation, a clinical-stage oncology company, engages in the development of medicines for broad populations of cancer patients. Its lead product candidates include IMM-1-104, a dual-MEK inhibitor currently under Phase 1/2a clinical trial to treat patients with cancer, including pancreatic, melanoma, colorectal, and non-small cell lung cancer caused by mutations of RAS and/or RAF; and IMM-6-415 is in Investigational New Drug application to treat solid tumors.